Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ongentys

- PMLiVE

BeiGene’s Brukinsa receives EC approval for chronic lymphocytic leukaemia

The drug showed better results than Imbruvica, a current standard of care treatment

- PMLiVE

Sanofi’s Enjaymo receives EC approval for rare autoimmune haemolytic anaemia

Cold agglutinin disease affects around 12,000 people in the US, Europe and Japan

- PMLiVE

Roche’s high-throughput monkeypox test approved for emergency use by FDA

The tests will be conducted on the company’s 6800/8800 cobas systems

- PMLiVE

Roche enters into second collaboration with Jnana to address complex drug targets

The Boston-based biotech will receive an upfront payment of $50m

- PMLiVE

AstraZeneca/Sanofi’s Beyfortus receives EC approval for prevention of RSV in infants

The decision makes the antibody the first broadly protective option for this age population

- PMLiVE

BeiGene’s Brukinsa receives EC approval for marginal zone lymphoma

The BTK inhibitor was also granted an additional year of marketing protection

- PMLiVE

Kite’s CAR-T therapy Yescarta granted EC approval in second-line lymphoma

The decision is based on results from the phase 2 ZUMA-7 study

- PMLiVE

New study finds signs of dementia could be detected nine years before diagnosis

Impairment was observed in several areas across a range of dementia-related diseases

- PMLiVE

Genentech shares positive two-year data for Evrysdi in spinal muscular atrophy study

The study enrolled the ‘broadest and most diverse’ patient population ever studied in an SMA trial

- PMLiVE

Michael J Fox Foundation awards $4.9m grant to Muna Therapeutics

The grant will support the development of the company’s disease modifying therapy for Parkinson's disease

- PMLiVE

Biogen and Denali dose first patients with LRRK2 inhibitor in Parkinson’s disease study

Mutations in the LRRK2 gene are one of the most common causes of familial Parkinson’s disease

- PMLiVE

Genentech and ArsenalBio join to identify successful T-cell oncology therapies

While CAR-T therapy has shown promise in blood cancers, solid tumours present additional challenges

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links